Skip to main content

letter

. 1991 Mar;63(3):476. doi: 10.1038/bjc.1991.111

The use of erythropoietin in a Jehovah's Witness undergoing major surgery and chemotherapy.

P W Johnson, R King, M L Slevin, H White

PMCID: PMC1971874 PMID: 2003993

476

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

Casati S., Passerini P., Campise M. R., Graziani G., Cesana B., Perisic M., Ponticelli C. Benefits and risks of protracted treatment with human recombinant erythropoietin in patients having haemodialysis. Br Med J (Clin Res Ed) 1987 Oct 24;295(6605):1017–1020. doi: 10.1136/bmj.295.6605.1017. [DOI] [PMC free article] [PubMed] [Google Scholar]
Eschbach J. W., Egrie J. C., Downing M. R., Browne J. K., Adamson J. W. Correction of the anemia of end-stage renal disease with recombinant human erythropoietin. Results of a combined phase I and II clinical trial. N Engl J Med. 1987 Jan 8;316(2):73–78. doi: 10.1056/NEJM198701083160203. [DOI] [PubMed] [Google Scholar]
Winearls C. G., Oliver D. O., Pippard M. J., Reid C., Downing M. R., Cotes P. M. Effect of human erythropoietin derived from recombinant DNA on the anaemia of patients maintained by chronic haemodialysis. Lancet. 1986 Nov 22;2(8517):1175–1178. doi: 10.1016/s0140-6736(86)92192-6. [DOI] [PubMed] [Google Scholar]

ACTIONS

RESOURCES